Ascomycins: promising agents for the treatment of inflammatory skin diseases.
about
Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patientsDermacase. Atrophic patchesOpportunities to minimise risk in drug discovery and development.Importance of microbial natural products and the need to revitalize their discovery.Immunotherapy in atopic dermatitis.Pimecrolimus for the treatment of inflammatory skin disease.Problem-based learning: a review of current issues relevant to physiotherapy education.Pimecrolimus for psoriasis.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.Ascomycin: an advance in the management of atopic dermatitis.Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment.Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.Topical pimecrolimus: a new horizon for vitiligo treatment?Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel®) for up to 1 year
P2860
Q24675365-E4AB8C59-BB2E-4257-9EA0-E7D128F25BD4Q24681907-0F0BACF6-1494-4A17-A4F1-2F74315AD2D5Q30428283-706EE4E6-58A5-4FD1-A226-35C2B7131104Q31128037-9777752C-4885-424F-BA95-58F44B9E48EFQ34104585-23E84D01-F6B3-4EFC-B08F-F32007B127E7Q35688189-0EC6E540-80C3-464F-8E9C-666E62168773Q36356956-9B0AA120-26A0-4F21-A24A-02F2E4499456Q38086585-4D99A533-7AA0-452F-9C5D-76843D180ABDQ38123240-49349771-805D-4FBA-B6F2-FC80759531F2Q43572222-38817E6D-D2FF-4721-BCD6-4DA0AA46F7A8Q44150677-B3917987-9346-4209-850D-6895FEE5BE9FQ46524678-0398126A-054A-451C-8621-6440645161A3Q46725937-BBB7E8F6-C9F0-425B-AE55-ABA1B384ED5DQ51737944-0759ECD3-CD73-4C0D-97AC-27A8F381AE12Q57698374-9BFB51EB-C423-41CC-B32D-CF5B44F03EAE
P2860
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@ast
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@en
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@nl
type
label
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@ast
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@en
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@nl
prefLabel
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@ast
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@en
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@nl
P2093
P2860
P356
P1476
Ascomycins: promising agents for the treatment of inflammatory skin diseases.
@en
P2093
P2860
P356
10.1517/13543784.9.1.69
P407
P577
2000-01-01T00:00:00Z